三個皮匠報告
政策庫
new
付費
搜索

中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例-行業數據

中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例
26.9%顯著改善至 57.7%，而安慰劑組幾乎無變化。與安慰劑組相比，耐賦康治療組 24 個月時無鏡下血尿的患者比例明顯更高。
其它 下載Excel 下載圖片 原圖定位
圖片屬性
圖片格式：PNG 圖片大?。?25KB 圖片尺寸：1808*712
同報告圖片
 / 36
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第1頁
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
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第2頁
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
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第3頁
fCBJZ0Hogr7nl4UgfCDlvq7lsI/nl4Xlj5jogr7nl4UgfCDns7vohpzlop7nlJ/mgKfogr7ngo4gfCDohpzmgKfogr7nl4UgfCDlsYDngbboioLmrrXmgKfogr7lsI/nkIPnoazljJYgfCDlhbbku5YgfCAgCnwtLS18LS0tfC0tLXwtLS18LS0tfC0tLXwgIAp8IDUzJSB8IDE4JSB8IDE1JSB8IDclIHwgMSUgfCA1JSB8
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第4頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第5頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第6頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第7頁
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
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第8頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第9頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第10頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第11頁
5aW955qE44CCCgrku6XkuIvmmK/lm77niYfkuK3nmoTmlbDmja7vvJoKfCDpobnnm64gfCDkuK3lm70gfCDlhajnkIMgfAp8IC0tLSB8IC0tLSB8IC0tLSB8CnwgTmVmZWNvbiAxNiBtZy/lpKkgfCAwLjQ2ICgwLjglKSB8IDAuNjYgKDEuMiUpIHwKfCDlronmhbDliYIgfCAtNi45MyAoLTExLjglKSB8IC00LjU2ICgtOC4yJSkgfAp8IE5lZmVjb24gMTYgbWcv5aSpIHwgLTcuMDkgKC0xMi4wJSkgfCAtNi4xMSAoLTExLjAlKSB8Cnwg5a6J5oWw5YmCIHwgLTIwLjk3ICgtMzUuNiUpIHwgLTEyLjAgKC0yMS41JSkgfAoK6LWE5paZ5p2l5rqQ77ya6IK+5Yy757q/5YWs5LyX5Y+377yM6ZW/5Z+O6K+B5Yi45Lqn5Lia6YeR6J6N56CU56m26Zmi
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第12頁
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
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第13頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第14頁
fCBDLUJyaWRnZSBJbnZlc3RtZW50IEV2ZXJlc3QgTGltaXRlZCB8IEMtQnJpZGdlIElWIEludmVzdG1lbnQgVHdvIExpbWl0ZWQgfCBFdmVyZXN0IE1hbmFnZW1lbnQgSG9sZGluZ3MgQ28uLCBMdGQgfCBDLUJyaWRnZSBJViBJbnZlc3RtZW50IE5pbmUgTGltaXRlZCB8IEV2ZXJlc3QgTWVkaWNpbmVzIExpbWl0ZWQgKOS6kemhtuaWsOiAgCwgMTk1Mi5ISykgfCBFdmVyZXN0IE1lZGljaW5lcyAoU2luZ2Fwb3JlKSB8IEV2ZXJlc3QgTWVkaWNpbmVzIChVUykgfCBFdmVyZXN0IE1lZGljaW5lcyBJSSB8IEV2ZXJvbiBNZWRpY2luZXMgSW5jLiB8IEV2ZXJOb3YgTWVkaWNpbmVzIExpbWl0ZWQgfAp8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8IC0tLSB8CnwgMTUuNDUlIHwgMTEuNTElIHwgNi45MyUgfCA0LjcyJSB8IDQwLjUwJSB8IDEwMCUgfCAxMDAlIHwgMTAwJSB8IDEwMCUgfCA5Mi44NiUgfAoK6LWE5paZ5p2l5rqQ77yaV2luZO+8jOWFrOWPuOaLm+iCoeS5pu+8jDIwMjPlubTmiqXvvIzplb/ln47or4HliLjkuqfkuJrph5Hono3noJTnqbbpmaIg5rOo77ya5pWw5o2u5oiq6IezMjAyM+W5tOaKpQ==
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第15頁
fCDpobnnm64gfCDnrKwyNeWRqCB8IOesrDM35ZGoIHwKfC0tLS0tLXwtLS0tLS0tLXwtLS0tLS0tLXwKfCBPUlIgMSB8IDY0LjclICB8IDg4LjIlICB8CnwgQ1JSIDIgfCAzNS4zJSAgfCA0MS4yJSAgfA==
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第16頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第17頁
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
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第18頁
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
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第19頁
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
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第20頁
fCDOseeri+S9k+e7k+aehOWvueS6jua0u+aAp+aYr+W/hemcgOeahO+8m0M05LqM55Sy6IO65Z+655qE56e75Yqo5Lya5a+86Ie05rS75oCn6ZmN5L2OIHwg5rCo5rCu54O35Z+65YyW5Lya5a+86Ie05rS75oCn6ZmN5L2OIHwg55So6Yab5oiW5Lqa56Gd6YW455uQ5Luj5pu/5Lya6ZmN5L2O5rS75oCnIHwgQzEx54O35Z+65YyW5Lya5a+86Ie05oqX55Sf57Sg5aSx5rS7IHwg6YWuLeeDr+mGh+S9k+ezu+WvueaVtOWQiOS9nOeUqOWNgeWIhumHjeimgSB8CnwgOi0tOiB8IDotLTogfCA6LS06IHwgOi0tOiB8IDotLTogfAp8IE4oQ0gzKTIgfCBPIHwgTkgyIHwgT0ggfCBPSCB8
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第21頁
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
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第22頁
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
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第23頁
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
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第24頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第25頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第26頁
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
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第27頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第28頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第29頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第30頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第31頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第32頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第33頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第34頁
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第35頁
fCDoja/lk4HlkI3np7AgfCDoja/nianov5vlsZUgfCDpo47pmanosIPmlbTns7vmlbAgUE9TIHwgMjAyM0EgfCAyMDI0RSB8IDIwMjVFIHwgMjAyNkUgfAp8LS0tLS0tLS0tLXwtLS0tLS0tLS0tLS0tLS0tfC0tLS0tLS0tLS0tLS0tLS0tLXwtLS0tLS0tLXwtLS0tLS0tLXwtLS0tLS0tLXwtLS0tLS0tLXwKfCDkvp3mi4nnjq/ntKAgfCDnvo7lm73jgIHmrKfnm5/jgIHoi7Hlm73jgIHmlrDliqDlnaHjgIHlpKfkuK3ljY7ljLrkuIrluIIgfCAtIHwgLSB8IDIuOCB8IDQuNyB8IDYuNyB8Cnwg6ICQ6LWL5bq3IHwg576O5Zu944CB5qyn55uf44CB5paw5Yqg5Z2h44CB5Lit5Zu95aSn6ZmG5Y+K5r6z6Zeo5LiK5biC77yb6Z+p5Zu944CB5Lit5Zu95Y+w5rm+6YCS5LqkIE5EQSB8IC0gfCAtIHwgNC4wIHwgMTIuMCB8IDE3LjMgfAp8IOS8iuabsuiOq+W+tyB8IOe+juWbveOAgeasp+ebn+OAgeS4reWbvea+s+mXqOS4iuW4gu+8m+S4reWbveWkp+mZhumAkuS6pCBOREEgfCAtIHwgLSB8IDAuMiB8IDAuNyB8IDIuNCB8Cnwg5aS05a2i5ZCh6IKfLeS7luWwvOehvOW3tOWdpiB8IOe+juWbvU5EQeiOt+W+l+S8mOWFiOWuoeivhO+8jOS4reWbveWkp+mZhuaLn+S6jjIwMjTlubTpgJLkuqQgTkRBIHwgNzAlIHwgLSB8IC0gfCAtIHwgMS44IHwKfCDlkIjorqEgfCAgfCAgfCAxLjMgfCA3LjAgfCAxNy41IHwgMjguMSB8CnwgWW9ZIHwgIHwgIHwgNDU4JSB8IDE0OSUgfCA2MSUgfCAgfAoK6LWE5paZ5p2l5rqQ77ya5YWs5Y+4MjAyM+W5tOaKpe+8jFdpbmTvvIzplb/ln47or4HliLjkuqfkuJrph5Hono3noJTnqbbpmaLpooTmtYs=
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第36頁
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
中國和全球耐賦康VS安慰劑組的無鏡下血尿的患者比例_第37頁
所屬報告： 云頂新耀~B-港股公司研究報告-腎病大單品順利商業化企業發展邁入快車道-240526（43頁）.pdf
打包全文圖表

相關數據

最新數據
聯系我們
  • 0731-84720580
  • sgpjbg002
  • 工作日 9:30 - 18:00
關于我們
侵權處理
關于我們

三個皮匠報告專業的行業報告下載站，每日更新，歡迎大家關注！

copyright@2008-2013 長沙景略智創信息技術有限公司版權所有
網站備案/許可證號：湘B2-20190120

客服
商務合作
小程序
服務號
折疊
午夜网日韩中文字幕,日韩Av中文字幕久久,亚洲中文字幕在线一区二区,最新中文字幕在线视频网站